Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
Incoming President and CEO John Milligan opened Gilead Sciences Inc.'s first quarter earnings call April 28 talking about sales growth of new HIV drugs and pipeline efforts in non-alcoholic steatohepatitis (NASH), but analysts focused in quickly on overall reductions in hepatitis C sales, including a more than 50% decrease year-over-year in US sales of Harvoni.
You may also be interested in...
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.
While HCV sales continue to slow due to a lengthy list of factors, Gilead is seeing a strong launch for revised HIV combo therapies incorporating TAF – but most analysts believe that major M&A is needed to offset stagnation.
As royalties from hepatitis C therapy simeprevir continue to decline its originator, Swedish biotech Medivir, is considering a separate public listing for its commercial operations that would allow the remaining concern to return to its previous R&D roots.